Antihypertensive drugs and risk of incident gout among patients with hypertension: Population based case-control study

BMJ (Online)

Volumn 344, Issue 7843, 2012, Pages

  Choi, Hyon K ^a   Soriano, Lucia Cea ^b   Zhang, Yuqing ^a   Garciá Rodriǵuez, Luis A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Pharmacoepidemiology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; NIFEDIPINE;

ADULT; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GOUT; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; GOUT; GREAT BRITAIN; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84863139274     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d8190     Document Type: Article

References (43)

1. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population - the National Health and Nutrition Examination Survey 2007-2008. Am J Med (In press).
2. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005;165:742-8. (Pubitemid 40569426)
3. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516. (Pubitemid 41379398)
4. Wyngaarden JB, Kelley WN. Gout and hyperuricemia. Grune & Stratton, 1976.
5. Prebis JW, Gruskin AB, Polinsky MS, Baluarte HJ. Uric acid in childhood essential hypertension. J Pediatr 1981;98:702-7. (Pubitemid 11070319)
6. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980;93:817-21. (Pubitemid 11197783)
7. Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension. N Engl J Med 1979;301:293-7.
8. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17:397-414. (Pubitemid 38339910)
9. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981;2:539-43.
10. Ruilope LM, Kirwan BA, de Brouwer S, Danchin N, Fox KA, Wagener G, et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens 2007;25:1711-8. (Pubitemid 47056580)
11. Chanard J, Toupance O, Lavaud S, Hurault de Ligny B, Bernaud C, Moulin B. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003;18:2147-53. (Pubitemid 37220324)
12. Burnier M, Waeber B, Brunner HR. Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects. J Hypertens Suppl 1995;13:S23-8.
13. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787-90. (Pubitemid 26186613)
14. Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999;56:1879-85. (Pubitemid 29518189)
15. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9. (Pubitemid 38251080)
16. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-79. (Pubitemid 38339177)
17. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7. (Pubitemid 39534583)
18. O'Neil M, Payne C, Read J. Read codes version 3: a user led terminology. Methods Inf Med 1995;34:187-92.
19. Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM. A language of health in action: Read codes, classifications and groupings. Proc AMIA Annu Fall Symp 1996:75-9.
20. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401. (Pubitemid 46656860)
21. Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol 1997;44:175-8. (Pubitemid 27327072)
22. Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology 2007;69:1696-700. (Pubitemid 350287126)
23. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am J Nephrol 2003;23:229-44. (Pubitemid 36980719)
24. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60. (Pubitemid 32924953)
25. Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268-71. (Pubitemid 28370013)
26. Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, Tanaka H, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002;41:793-7. (Pubitemid 35314777)
27. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001;23:1166-79. (Pubitemid 32804112)
28. Gonzalez-Ortiz M, Mora-Martinez JM, Martinez-Abundis E, Balcazar-Munoz BR. Effect of valsartan on renal handling of uric acid in healthy subjects. J Nephrol 2000;13:126-8. (Pubitemid 30260880)
29. Monterroso VH, Rodriguez Chavez V, Carbajal ET, Vogel DR, Aroca Martinez GJ, Garcia LH, et al. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators. Adv Ther 2000;17:117-31. (Pubitemid 30419040)
30. Muller P, Flesch G, de Gasparo M, Gasparini M, Howald H. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 1997;52:441-9. (Pubitemid 27395643)
31. Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000;22:1186-203.
32. Burgess ED, Buckley S. Acute natriuretic effect of telmisartan in hypertensive patients. Am J Hypertens 2000;13:183A.
33. McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996;28:101-6.
34. Puig JG, Torres R, Ruilope LM. AT1 blockers and uric acid metabolism: are there relevant differences? J Hypertens Suppl 2002;20:S29-31. (Pubitemid 34925657)
35. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033-9. (Pubitemid 29322193)
36. Ilson BE, Martin DE, Boike SC, Jorkasky DK. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 1998;38:437-41. (Pubitemid 28224217)
37. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447-52. (Pubitemid 34563537)
38. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008;21:1157-62.
39. Leary WP, Reyes AJ, Wynne RD, van der Byl K. Renal excretory actions of furosemide, of hydrochlorothiazide and of the vasodilator flosequinan in healthy subjects. J Int Med Res 1990;18:120-41. (Pubitemid 20123938)
40. Hunter DJ, York M, Chaisson CE, Woods R, Niu J, Zhang Y. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006;33:1341-5. (Pubitemid 44026423)
41. Andersen GS. Atenolol versus bendroflumethiazide in middle-aged and elderly hypertensives. Acta Med Scand 1985;218:165-72. (Pubitemid 16240414)
42. Pedersen OL, Jacobsen FK, Stengaard-Pedersen K. Renal uric acid handling is not affected by beta-adrenoceptor blockade in normotensive subjects. Eur J Clin Pharmacol 1985;28:223-4.
43. Malini PL, Strocchi E, Cervi V, Ambrosioni E. The metabolic effects of enalapril. Clin Exp Hypertens A 1987;9:675-9. (Pubitemid 17096605)